Clinical Trials Directory

Trials / Terminated

TerminatedNCT02303158

Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression

Study of the Relationship Between Protein Biomarkers in Cerebrospinal Fluid and the Risk of Progression to Alzheimer&Apos;s Disease in a Cohort of Patients With Depression

Status
Terminated
Phase
Study type
Observational
Enrollment
50 (actual)
Sponsor
Institut Investigacio Sanitaria Pere Virgili · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

It is currently accepted that depression during midlife is a risk factor for Alzheimer's disease (AD). Furthermore, several prospective population studies have demonstrated that depression is an independent risk factor for incident dementia of different types (e.g. vascular, mixed, Alzheimer's disease). However, it is not clear, what are the mechanisms that link depression and dementia, and if depression can be a prodromal manifestation of AD. There are also studies that suggest that depression could be an initial sign of AD. Objective: 1. Demonstrate that late life depression (over 60 years of age) constitutes the first manifestation of AD. 2. Define by rating scales and life stressors have differential risk profiles evolutionary AD. 3. To study the relationship between the subtypes of depression and CSF biomarkers, neurophycological test and evolution to AD.

Detailed description

Groups of subjects: patients with recent apparition of late life depression without fulfilling the dementia criteria (Global Deterioration Scale, GDS, stages 1, 2 and 3). A longitudinal, prospective population study with two years follow-up. A cohort of will be included in the study. The patient's depression will be defined and categorized according to its severity (Yesavage Scale), whether it's endogenous or reactive (Holmes and Rahe scale) and taking into account the patient's medical history of depression. There will be a prospective follow-up of conversion to dementia (starting from GDS Stage 4). It will be considered that dementia corresponds to AD if the biological markers of LCR present typical changes of AD at the moment of inclusion (Beta amyloid low and P-tau high). It will be studied if there's any correlation between the clinically defined depression types and a high risk of progression to dementia and especially to AD.

Conditions

Timeline

Start date
2014-01-01
Primary completion
2016-02-01
Completion
2018-10-01
First posted
2014-11-27
Last updated
2018-10-09

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT02303158. Inclusion in this directory is not an endorsement.